Synapse - Glenn Heller

Search Within

Glenn Heller

Results (400)

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas

Journal Article

Selenica, P.; Marra, A.; Choudhury, N. J.; Gazzo, A.; Falcon, C. J.; Patel, J.; Pei, X.; Zhu, Y.; Ng, C. K. Y.; Curry, M.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Inhibition of NF-κB DNA binding suppresses myeloma growth via intracellular redox and tumor microenvironment modulation

Journal Article

Bariana, M.; Cassella, E.; Rateshwar, J.; Ouk, S.; Liou, H. C.; Heller, C.; Colorado, I.; Feinman, R.; Makhdoom, A.; Siegel, D. S.; more...
Molecular Cancer Therapeutics (2022)

Fulltext@MSK | Save

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers

Meeting Abstract

Choudhury, N. J.; Marra, A.; Yang, S. R.; Falcon, C. J.; Heller, G.; Kris, M. G.; Reis-Filho, J. S.; Riely, G. J.; Yu, H. A.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy

Journal Article

Hasan, A. N.; Doubrovina, E.; Sottile, R.; Prockop, S.; Klatt, M. G.; Heller, G.; Selvakumar, A.; Barnett, L.; Hsu, K. C.; O’Reilly, R. J.
Blood Advances (2022)

Fulltext@MSK | Save

Automated bone scan index to optimize prostate cancer working group radiographic progression criteria for men with metastatic castration-resistant prostate cancer

Journal Article

Anand, A.; Heller, G.; Fox, J.; Danila, D. C.; Bjartell, A.; Edenbrandt, L.; Larson, S. M.; Scher, H. I.; Morris, M. J.
Clinical Genitourinary Cancer (2022)

Fulltext@MSK | Save

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Immune biomarkers and response to checkpoint inhibition of BRAF(V600) and BRAF non-V600 altered lung cancers

Journal Article

Murciano-Goroff, Y. R.; Pak, T.; Mondaca, S.; Flynn, J. R.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Plodkowski, A. J.; Wu, S. L.; Kris, M. G.; more...
British Journal of Cancer (2022)

Fulltext@MSK | Save

Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy

Journal Article

Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
European Urology Open Science (2021)

Fulltext@MSK | Save

A phase II, nonrandomized open trial assessing pain efficacy with radium-223 in symptomatic metastatic castration-resistant prostate cancer

Journal Article

McHugh, D.; Tagawa, S.; Moryl, N.; Milowsky, M.; Heller, G.; Osborne, J.; Rathkopf, D.; Basch, E.; Pandit-Taskar, N.; Morris, M. J.
Clinical Genitourinary Cancer (2021)

Fulltext@MSK | Save